Replies to post #181075 on Arrayit Corporation (ARYC)

[Alyssa]

Testing accuracy has been excellent in their allergy/asthma program, so why not in the COVID-19 test with the very same sampling method.

Sunnyvale, May 20, 2019 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, announces that its clinical laboratory has aced five consecutive rounds of diagnostic immunology proficiency testing (PT) spanning three fiscal years 2017-2019. Proficiency testing requires the precise and accurate measurement of immunoglobulin E (IgE), the cellular biomarkers associated with allergy and asthma and reported in the company’s allergy test reports. A proficiency testing leader ships blinded specimens to Arrayit for testing, and Arrayit tests the specimens and reports the results for scoring to the independent agency. Because the acceptable test range is narrow, acing five consecutive rounds of PT is extremely demanding and requires a high degree of testing accuracy. Outstanding PT scores are valuable commercially because they expedite reimbursement by Medicare, Medicaid and the top commercial payors.